MX2016005762A - Region variable de anticuerpo modificada que contiene molecula de union al antigeno. - Google Patents
Region variable de anticuerpo modificada que contiene molecula de union al antigeno.Info
- Publication number
- MX2016005762A MX2016005762A MX2016005762A MX2016005762A MX2016005762A MX 2016005762 A MX2016005762 A MX 2016005762A MX 2016005762 A MX2016005762 A MX 2016005762A MX 2016005762 A MX2016005762 A MX 2016005762A MX 2016005762 A MX2016005762 A MX 2016005762A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- binding molecule
- variable region
- antibody variable
- molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a una molécula de unión al antígeno que comprende una región variable de anticuerpo que tiene actividad de unión contra una molécula expresada en la superficie de una célula T y una molécula expresada en la superficie de cualquier otro inmunocito, pero no se une a estas moléculas al mismo tiempo. La presente invención permite la preparación de una molécula que se une al antígeno capaz de eludir reacciones adversas que pueden ser causadas por la reticulación de células T a otros inmunocitos, y proporciona una molécula que se une al antígeno adecuada como un fármaco.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013232803 | 2013-11-11 | ||
PCT/JP2014/079785 WO2015068847A1 (ja) | 2013-11-11 | 2014-11-11 | 改変された抗体可変領域を含む抗原結合分子 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016005762A true MX2016005762A (es) | 2016-08-19 |
Family
ID=53041619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005762A MX2016005762A (es) | 2013-11-11 | 2014-11-11 | Region variable de anticuerpo modificada que contiene molecula de union al antigeno. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20160280787A1 (es) |
EP (1) | EP3070168A4 (es) |
JP (3) | JPWO2015068847A1 (es) |
KR (2) | KR20230104764A (es) |
CN (3) | CN105940107B (es) |
AU (1) | AU2014347565B2 (es) |
BR (1) | BR112016010025A2 (es) |
CA (1) | CA2929044A1 (es) |
EA (1) | EA201600354A1 (es) |
MX (1) | MX2016005762A (es) |
TW (2) | TWI712421B (es) |
WO (1) | WO2015068847A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2862875B1 (en) | 2012-06-14 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
TWI712421B (zh) | 2013-11-11 | 2020-12-11 | 日商中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
EP3219724A4 (en) * | 2014-11-11 | 2018-09-26 | Chugai Seiyaku Kabushiki Kaisha | Library of antigen-binding molecules including modified antibody variable region |
WO2016182064A1 (ja) | 2015-05-13 | 2016-11-17 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
BR112019012901A2 (pt) | 2016-12-22 | 2020-01-07 | Daiichi Sankyo Company, Limited | Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula |
WO2018156106A1 (en) * | 2017-02-22 | 2018-08-30 | Ding Enyu | An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes |
US20200109205A1 (en) * | 2017-03-31 | 2020-04-09 | The Regents Of The University Of California | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers |
US11952422B2 (en) | 2017-12-05 | 2024-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 |
US20200399373A1 (en) * | 2018-02-14 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule and combination |
WO2019161386A1 (en) * | 2018-02-19 | 2019-08-22 | New York University | Alpha-synuclein single domain antibodies |
SG11202102882YA (en) * | 2018-09-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule comprising altered antibody variable region |
AU2019347412A1 (en) * | 2018-09-28 | 2021-05-27 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules capable of binding CD3 and CD137 but not simultaneously |
JP2022538374A (ja) * | 2019-06-28 | 2022-09-02 | 中外製薬株式会社 | Pdgf-bおよびpdgf-dに結合する抗原結合分子ならびにその使用 |
CN112794914B (zh) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | 一种基于噬菌体展示技术开发的alk纳米抗体及其应用 |
US20230121511A1 (en) * | 2020-03-31 | 2023-04-20 | Chugai Seiyaku Kabushiki Kaisha | Method for producing multispecific antigen-binding molecules |
JP7085666B2 (ja) | 2020-03-31 | 2022-06-16 | 中外製薬株式会社 | Dll3標的多重特異性抗原結合分子およびその使用 |
EP4159765A1 (en) * | 2020-06-01 | 2023-04-05 | Mustbio Co., Ltd. | Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor |
WO2023081266A2 (en) * | 2021-11-03 | 2023-05-11 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Molecules that bind to protogenin (prtg) polypeptides |
CN116178567A (zh) * | 2022-10-28 | 2023-05-30 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
WO1992019973A1 (en) | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
WO1994018221A1 (en) * | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
JP2002522029A (ja) | 1998-07-27 | 2002-07-23 | ジェネンテック・インコーポレーテッド | コートタンパク質の改変によるファージ提示における改良した形質転換効率 |
AU1219000A (en) | 1998-10-22 | 2000-05-08 | Regents Of The University Of California, The | Functionally assembled antigen-specific intact recombinant antibody and a methodfor production thereof |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US20100081792A1 (en) * | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
EP2154157A3 (en) | 2004-01-12 | 2010-04-28 | Applied Molecular Evolution Inc. | FC region variants |
DE602005027309D1 (de) | 2004-01-16 | 2011-05-19 | Regeneron Pharma | Zur aktivierung von rezeptoren fähige fusionspolypeptide |
SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
EP1778726A4 (en) * | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
SI1797127T1 (sl) | 2004-09-24 | 2017-09-29 | Amgen Inc. | Modificirane fc-molekule |
JP2008518023A (ja) * | 2004-10-27 | 2008-05-29 | メディミューン,インコーポレーテッド | 同族抗原に対する親和性を改変することによる抗体特異性の調節 |
CN101123983A (zh) * | 2004-10-27 | 2008-02-13 | 米迪缪尼股份有限公司 | 特定修饰对相关抗原的亲和力来调节抗体的特异性 |
EP2325207B1 (en) | 2004-11-12 | 2017-03-15 | Xencor, Inc. | FC variants with altered binding to FCRN |
PL1772465T3 (pl) | 2005-01-05 | 2009-08-31 | F Star Biotechnologische Forschungs Und Entw M B H | Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność |
CA2596248A1 (en) | 2005-01-31 | 2006-08-10 | Vaxinnate Corporation | Method to identify polypeptide toll-like receptor (tlr) ligands |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
EP1870458B1 (en) | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2 STRUCTURAL ISOMERS |
CN101262885B (zh) * | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
CA2611726C (en) | 2005-06-10 | 2017-07-11 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(fv)2 |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
WO2007121354A2 (en) | 2006-04-14 | 2007-10-25 | Trubion Pharmaceuticals Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
EP2522678A1 (en) | 2006-05-15 | 2012-11-14 | Sea Lane Biotechnologies, LLC | Neutralizing antibodies to influenza viruses |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
PT2155783E (pt) | 2007-04-03 | 2013-11-07 | Amgen Res Munich Gmbh | Domínio de ligação específico inter-espécies |
WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
WO2009011941A2 (en) | 2007-04-04 | 2009-01-22 | The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services | Monoclonal antibodies against dengue and other viruses with deletion in fc region |
SG10201605394SA (en) | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
WO2009086320A1 (en) | 2007-12-26 | 2009-07-09 | Xencor, Inc | Fc variants with altered binding to fcrn |
KR20100116179A (ko) | 2008-01-11 | 2010-10-29 | 고쿠리츠다이가쿠호우진 도쿄다이가쿠 | 항-cldn6 항체 |
WO2009099961A2 (en) | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
NZ623716A (en) | 2008-04-11 | 2016-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2283358B1 (en) | 2008-04-29 | 2015-04-22 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
EP2324061B1 (en) * | 2008-09-03 | 2017-04-12 | F. Hoffmann-La Roche AG | Multispecific antibodies |
CN105601745B (zh) | 2008-09-26 | 2020-09-08 | Ucb医药有限公司 | 生物产品 |
ES2732191T3 (es) | 2008-12-19 | 2019-11-21 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
RU2675997C2 (ru) | 2009-11-11 | 2018-12-25 | Ганимед Фармасьютикалз Аг | Антитела, специфичные к клаудину 6 (cldn6) |
DK2530091T3 (en) | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
KR102152109B1 (ko) | 2010-04-20 | 2020-09-07 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
RU2624027C2 (ru) | 2010-04-23 | 2017-06-30 | Дженентек, Инк. | Получение гетеромультимерных белков |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
CN103328514B (zh) | 2010-11-09 | 2015-12-02 | 阿尔蒂单抗治疗公司 | 用于抗原结合的蛋白复合物及其使用方法 |
LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
US20140080153A1 (en) | 2011-01-07 | 2014-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
EP2663334A4 (en) | 2011-01-10 | 2016-01-13 | Univ Emory | ANTIBODIES AGAINST INFLUENZA |
MX348071B (es) | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
NZ706004A (en) | 2011-05-13 | 2016-12-23 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer expressing claudin 6 |
CA2836857C (en) * | 2011-05-21 | 2019-12-03 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
US9238689B2 (en) | 2011-07-15 | 2016-01-19 | Morpho Sys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT) |
MY169358A (en) | 2011-08-23 | 2019-03-26 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
US9868774B2 (en) * | 2011-10-20 | 2018-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD22 chimeric antigen receptors |
CN109897103B (zh) | 2011-11-04 | 2024-05-17 | 酵活英属哥伦比亚有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
MX2014010074A (es) | 2012-02-24 | 2014-09-12 | Stem Centrx Inc | Moduladores de ligando de tipo delta 3 (dll3) y metodos de uso. |
TWI797443B (zh) | 2012-05-30 | 2023-04-01 | 日商中外製藥股份有限公司 | 抗原結合分子之篩選或製造方法 |
EP2862875B1 (en) * | 2012-06-14 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
MX369276B (es) | 2012-11-13 | 2019-11-04 | Biontech Ag | Agentes para tratamiento de enfermedades cancerosas que expresan claudina. |
WO2014075697A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
SI2968520T1 (sl) | 2013-03-14 | 2022-01-31 | Macrogenics, Inc. | Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor |
AU2014346792A1 (en) | 2013-11-06 | 2016-06-02 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
TWI712421B (zh) | 2013-11-11 | 2020-12-11 | 日商中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
US20170274072A1 (en) | 2014-03-26 | 2017-09-28 | Tohoku University | Bispecific antibody targeting human epidermal growth factor receptor |
PL3130606T3 (pl) | 2014-04-07 | 2022-02-07 | Chugai Seiyaku Kabushiki Kaisha | Przeciwciała dwuswoiste aktywujące układ odpornościowy |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3219724A4 (en) | 2014-11-11 | 2018-09-26 | Chugai Seiyaku Kabushiki Kaisha | Library of antigen-binding molecules including modified antibody variable region |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
US11952422B2 (en) | 2017-12-05 | 2024-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 |
EP3732195A4 (en) | 2017-12-28 | 2022-02-09 | Chugai Seiyaku Kabushiki Kaisha | CYTOTOXICITY-INDUCING THERAPEUTIC |
JP2021510064A (ja) | 2018-01-05 | 2021-04-15 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
SG11202102882YA (en) | 2018-09-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule comprising altered antibody variable region |
AU2019347412A1 (en) | 2018-09-28 | 2021-05-27 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules capable of binding CD3 and CD137 but not simultaneously |
TWI770917B (zh) | 2020-03-31 | 2022-07-11 | 日商中外製藥股份有限公司 | 密連蛋白6靶向多特異性抗原結合分子及其用途 |
JP2021175391A (ja) | 2020-03-31 | 2021-11-04 | 中外製薬株式会社 | 免疫活性化多重特異性抗原結合分子およびその使用 |
JP7085666B2 (ja) | 2020-03-31 | 2022-06-16 | 中外製薬株式会社 | Dll3標的多重特異性抗原結合分子およびその使用 |
US20230121511A1 (en) | 2020-03-31 | 2023-04-20 | Chugai Seiyaku Kabushiki Kaisha | Method for producing multispecific antigen-binding molecules |
-
2014
- 2014-11-11 TW TW108101781A patent/TWI712421B/zh active
- 2014-11-11 CN CN201480072799.3A patent/CN105940107B/zh active Active
- 2014-11-11 WO PCT/JP2014/079785 patent/WO2015068847A1/ja active Application Filing
- 2014-11-11 MX MX2016005762A patent/MX2016005762A/es unknown
- 2014-11-11 CN CN202110577978.4A patent/CN113307873A/zh active Pending
- 2014-11-11 KR KR1020237022012A patent/KR20230104764A/ko not_active Application Discontinuation
- 2014-11-11 CA CA2929044A patent/CA2929044A1/en active Pending
- 2014-11-11 US US15/035,098 patent/US20160280787A1/en not_active Abandoned
- 2014-11-11 JP JP2015546719A patent/JPWO2015068847A1/ja not_active Withdrawn
- 2014-11-11 TW TW103138989A patent/TWI652279B/zh active
- 2014-11-11 KR KR1020167015015A patent/KR102551410B1/ko active IP Right Grant
- 2014-11-11 BR BR112016010025A patent/BR112016010025A2/pt active Search and Examination
- 2014-11-11 CN CN202110579555.6A patent/CN113278076A/zh active Pending
- 2014-11-11 EA EA201600354A patent/EA201600354A1/ru unknown
- 2014-11-11 EP EP14859814.7A patent/EP3070168A4/en active Pending
- 2014-11-11 AU AU2014347565A patent/AU2014347565B2/en active Active
-
2019
- 2019-12-05 US US16/704,464 patent/US11739149B2/en active Active
-
2020
- 2020-08-25 JP JP2020141381A patent/JP7512129B2/ja active Active
-
2022
- 2022-10-20 JP JP2022168321A patent/JP2022191448A/ja active Pending
-
2023
- 2023-06-30 US US18/345,750 patent/US20240026000A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2014347565B2 (en) | 2020-08-13 |
US20200332001A1 (en) | 2020-10-22 |
KR102551410B1 (ko) | 2023-07-04 |
CA2929044A1 (en) | 2015-05-14 |
TW201605900A (zh) | 2016-02-16 |
BR112016010025A2 (pt) | 2017-12-05 |
CN105940107B (zh) | 2021-06-15 |
TW201919701A (zh) | 2019-06-01 |
EP3070168A4 (en) | 2017-06-28 |
CN105940107A (zh) | 2016-09-14 |
TWI712421B (zh) | 2020-12-11 |
US20240026000A1 (en) | 2024-01-25 |
US20160280787A1 (en) | 2016-09-29 |
JPWO2015068847A1 (ja) | 2017-03-09 |
KR20160083094A (ko) | 2016-07-11 |
JP7512129B2 (ja) | 2024-07-08 |
CN113278076A (zh) | 2021-08-20 |
KR20230104764A (ko) | 2023-07-10 |
TWI652279B (zh) | 2019-03-01 |
EA201600354A1 (ru) | 2016-12-30 |
US11739149B2 (en) | 2023-08-29 |
EP3070168A1 (en) | 2016-09-21 |
JP2022191448A (ja) | 2022-12-27 |
JP2020196741A (ja) | 2020-12-10 |
WO2015068847A1 (ja) | 2015-05-14 |
CN113307873A (zh) | 2021-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016005762A (es) | Region variable de anticuerpo modificada que contiene molecula de union al antigeno. | |
NZ750707A (en) | Cot modulators and methods of use thereof | |
MX2022012089A (es) | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos. | |
PH12015502039A1 (en) | Anti-lag-3 binding proteins | |
MX2014012978A (es) | Regiones de anticuerpo modificado y sus usos. | |
EA201592105A1 (ru) | Толерогенные синтетические наноносители и терапевтические макромолекулы для снижения или усиления фармакодинамических эффектов | |
SG10201902380SA (en) | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases | |
NZ719840A (en) | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof | |
WO2014197849A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
MX2015013163A (es) | Complejos multiespecificos multivalente y monovalentes y sus usos. | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201592076A1 (ru) | Антитела против cd38 и слитые белки с ослабленным интерфероном альфа-2b | |
WO2015195555A8 (en) | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells | |
NZ703423A (en) | Antibodies to tau | |
PH12015502126A1 (en) | Human pac1 antibodies | |
IN2015DN00636A (es) | ||
NZ738538A (en) | 6-amino-quinoline-3-carbonitrils as cot modulators | |
MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
EP4282881A3 (en) | Antibodies against csf-1r | |
IN2015DN00634A (es) | ||
PH12016500753B1 (en) | Antibodies specific to fcrn | |
AU2014225575A8 (en) | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same | |
AU2014249346A8 (en) | High purity ovarian cancer stem cells for active autologous immune therapy | |
MX2013011092A (es) | Antidotos anticoagulantes. | |
EA201890439A1 (ru) | ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА) |